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1607-551X/Copyright ª 2014, KaohsiuAbstract Laryngeal microsurgery is performed to assess disorders of the larynx. Parecoxib is
the only parenterally administered selective cyclooxygenase (COX)-2 inhibitor widely used in
acute pain control. The purpose of this study is to assess the analgesic effects of parecoxib
compared with morphine for postoperative sore throat in patients undergoing laryngeal micro-
surgery. Fifty patients were randomly allocated to receive either parecoxib 0.5 mg/kg or
morphine 50 mg/kg prior to anesthesia induction. General anesthesia was maintained with se-
voflurane 2e4%. Postoperative sore throat and other outcomes were measured at a posta-
nesthesia care unit (PACU) 4 hours and 24 hours postoperatively. The severity of
postoperative sore throat was assessed by sore throat score as follows: none (0)Z no pharyn-
geal or laryngeal discomfort; mild (1) Z no pain at rest, but swallowing induced mild pain or
discomfort; moderate (2) Z constant pain without swallowing exacerbation; and severe
(3) Z constant pain with swallowing or respiratory exacerbation. The incidences of postoper-
ative side effects (nausea, vomiting, itching, dizziness, and somnolence) were also recorded.
Demographic data from the parecoxib (n Z 25) and morphine (n Z 25) groups did not differ
significantly. The parecoxib group depicted similar sore throat scores as the morphine group
at three measured postoperative time points. Patients requiring postoperative analgesics were
comparable between the parecoxib group and morphine group (2/25, 8% vs. 3/25, 12%,
p Z 0.64). Overall postoperative adverse events were fewer in the parecoxib group than
the morphine group (3/25, 12% vs. 9/25, 36%, p Z 0.047). Both parecoxib and morphine are
effective to attenuate postoperative sore throat after laryngeal microsurgery. Parecoxibeclare no conflicts of interest.
t of Anesthesiology, Kaohsiung Municipal Ta-Tung Hospital, No. 68, Jhonghua 3rd Road, Kaohsiung,
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Parecoxib for laryngeal microsurgery 575may be an effective and well-tolerated injectable analgesic to manage postoperative sore
throat after laryngeal microsurgery.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Laryngeal microsurgery is performed to assess disorders of
the larynx. These procedures vary from biopsy to remove
or augment abnormal areas in the larynx and hypophar-
ynx. Patients might experience a mild to moderate sore
throat for several days, depending on the extent of the
surgery. Patients undergoing laryngeal microsurgery usu-
ally require general anesthesia with an endotracheal tube,
and many of them experience postoperative sore throat.
The leading causes of postoperative sore throat may be
the suspension of the laryngoscope during surgery and
tracheal intubation [1].
In most clinical settings, systemic administration of an-
algesics is a widely used method to reduce postoperative
pain. In addition to opioids, nonsteroidal anti-inflammatory
drugs (NSAIDs) play an important role. The analgesic effect
of NSAIDs is based on a diminished prostaglandin synthesis
by inhibition of the cyclooxygenase (COX) enzyme in the
arachidonic acid metabolism. The development of selective
COX-2-inhibitors (coxibs) has been demonstrated to
improve the risk-benefit ratio compared with traditional
NSAIDs [2]. Parecoxib is the only parenterally administered
selective COX-2-inhibitor widely used to treat post-
operative pain in such procedures as gynecologic and or-
thopedic surgery [3e6]. Whether parecoxib shows the same
analgesic effect as morphine in postoperative sore throat
after laryngeal microsurgery has not yet been determined.
The purpose of this study was to assess the analgesic effect
of parecoxib compared with morphine for postoperative
sore throat in patients undergoing laryngeal microsurgery.Materials and methods
With approval of the Institutional Review Board of Kaoh-
siung Medical University Hospital (protocol No: KMUH-IRB-
20110068), 60 patients undergoing laryngeal microsurgery
were eligible for this prospective, randomized, double-
blind study. Inclusion criteria were the following: patients
undergoing laryngeal microsurgery, aged between 18 years
and 75 years and having American Society of Anesthesiol-
ogists physical status IeIII. Patients with a history of sig-
nificant cardiac, pulmonary, hepatic, or renal disease, body
mass index <18.5 or >35, body weight over 80 kg, chronic
drug or alcohol abuse, and contraindications or previous
adverse reaction to morphine or parecoxib to be used in the
study were excluded.
After obtaining informed consent, each patient was
randomly assigned into parecoxib or morphine groups.
Randomization was performed using a sealed opaque en-
velope with a computer-generated block random alloca-
tion. The patients received the drugs (parecoxib 0.5 mg/kgor morphine 50 mg/kg) dissolved in 5 mL normal saline via
intravenous infusion over 5 minutes.
All patients had fasted overnight and no premedication
was given before induction of anesthesia. The use of opi-
oids (fentanyl) was avoided during anesthesia induction or
the intraoperative period. On arrival at the operating room,
a 22-gauge cannula was inserted into a forearm vein and
standard monitors were applied. Heart rate and oxygen
saturation were monitored continuously, and noninvasive
arterial blood pressure was recorded every 5 minutes
throughout anesthesia.
After 3 minutes of administration of oxygen, all patients
underwent anesthesia induction with 1 mg/kg lidocaine and
5 mg/kg thiamylal, followed by 0.3 mg/kg rocuronium to
facilitate tracheal intubation. Another bolus of propofol
1.0 mg/kg was administrated immediately before intuba-
tion. The study analgesics were injected prior to endotra-
cheal intubation via direct laryngoscopy by one
experienced anesthesiologist. General anesthesia was
maintained with sevoflurane 2e4%. After the surgical pro-
cedure, the patients were directly transferred to the
postanesthesia care unit (PACU), where an independent,
blinded observer recorded further clinical observations.
Postoperative record
The primary endpoint was postoperative sore throat
measured at the PACU, 4 hours and 24 hours postoperatively.
The severity of postoperative sore throatwas assessedby sore
throat score as per previous literature [7]: none, 0 Z no
pharyngeal or laryngeal discomfort;mild, 1Z no pain at rest,
but swallowing induced mild pain or discomfort; moderate,
2Z constant pain without swallowing exacerbation; and se-
vere, 3 Z constant pain with swallowing or respiratory
exacerbation. Analgesic effect was also assessed during a 24-
hour treatment period, using the standardmeasures: baseline
sore throat intensity, pain relief, and the time to rescue
medication. Pain relief was measured by a five-point scale;
0 Z none, 1 Z little, 2 Z moderate, 3 Z good, and
4Z complete. Rescue analgesics weremorphine 50 mg/kg for
inadequate pain relief. If respiratory depression developed
after intravenous morphine, airway management and venti-
lation support with oxygen therapy were given.
Other parameters were recorded as follows. Hemody-
namic variables were compared at arrival at the PACU. The
incidence of postoperative side effects (nausea, vomiting,
pruritus, dizziness, and somnolence) was quantified using
different scales. The scale for postoperative vomiting was
0Z none, 1Z one or two episodes, and 3Zmore than two
episodes. The scale for others was 0 Z none, 1 Z mild,
2 Z moderate, and 3 Z severe. The patient’s satisfaction
of study medication was measured by a four-point scale;
1 Z poor; 2 Z fair; 3 Z good; and 4 Z excellent.
Table 1 Patient characteristics between groups.
Parecoxib
group (n Z 25)
Morphine
group (n Z 25)
p
Sex (M:F) 11:14 15:10 0.26
Age (y) 43.9  13.4 50.9  13.1 0.07
Weight (kg) 64.4  11.1 64.7  11.6 0.91
Height (cm) 161.8  7.8 163.2  7.5 0.51
ASA I/II/III (n) 4/17/4 2/20/3 0.59
Benign
disease (n)
16 (64) 18 (72) 0.54
Operation
period (min)
35.4  16.7 31.8  15.5 0.43
Data are presented as n (%) or mean  SD, unless otherwise
indicated.
ASA Z American Society of Anesthesiologists.
576 H.-F. Huang et al.According to the assumptions that (1) parecoxib 0.5 mg/
kg would produce a 50% decrease in the sore throat score
and (2) a type I error a Z 0.05 and power of 0.9, a power
analysis suggested a sample size of 14 patients for each
group. The trial enrolled 30 cases to ensure power. Differ-
ences between the two groups were calculated by the
Student t test. Categorical data were analyzed using c2 or
Fisher’s exact test as appropriate. A value of p < 0.05 was
considered statistically significant.
Results
Fifty patients were complete in the study as per the
flowchart (Fig. 1), and all patients had undergone laryn-
geal microsurgery. There were no significant differences
across the groups in the baseline characteristics of the
patients (Table 1). The study showed that patients expe-
rienced similar relief from sore throat pain with intrave-
nous parecoxib sodium and morphine. The parecoxib
group depicted similar sore throat scores as the morphine
group at baseline and three measured time points post-
operatively (Table 2). The median (range) sore throat
score was 2 (0e3) in the parecoxib group and 1 (0e3) in
the morphine group (p Z 0.15) at PACU. The median
(range) sore throat score was 1 (0e3) in the parecoxib
group and 1 (0e3) in the morphine group (p Z 0.33) at 4
hours after surgery. The median (range) sore throat score
was 0 (0e3) in the parecoxib group and 1 (0e3) in the
morphine group (p Z 0.57) 24 hours after surgery. The
proportion of patients who took rescue medication was
similar for both groups (Table 2). Patients requiringAllocated to parecoxib (n = 28) 
  Received allocated parecoxib (n = 26) 
  Did not receive allocated parecoxib (n = 2) 
     Operation cancelled (n = 1) 
     Unexpected difficult laryngoscopy (n = 1)
Randomized
Patients undergoi
LMS for eligibilit
Lost to follow up (n = 1) 
Discontinued intervention (n = 0) 
Analysed (n = 25) 
  Excluded from analysis (n = 0) 
Figure 1. Trpostoperative analgesics were comparable between the
parecoxib group and morphine group (2/25, 8% vs. 3/25,
12%, p Z 0.64). Common adverse events recorded in the
study are listed in Table 3. Overall, postoperative adverse
events were fewer in the parecoxib group (Table 3). Most
patients rated their medication satisfaction as “good” or
“excellent” in both groups.
Discussion
In patients undergoing laryngeal microsurgery, our primary
outcome demonstrated that single-dose parecoxib provided (n = 55)
Excluded (n = 5) 
  Not meeting inclusion criteria (n = 3) 
  Declined to participate (n = 2) 
ng elective 
y (n = 60) 
Allocated to morphine (n = 27) 
  Received allocated morphine (n = 25) 
  Did not receive allocated morphine (n = 2) 
     Unexpected difficult laryngoscopy (n = 2) 
Lost to follow up (n = 0) 
Discontinued intervention (n = 0) 
Analysed (n = 25) 
  Excluded from analysis (n = 0) 
ial profile.
Table 2 Postoperative sore throat in patients receiving
parecoxib or morphine.
Parecoxib
group (n Z 25)
Morphine
group (n Z 25)
p
Preoperative 19/6/0/0 17/8/0/0 0.53
0/1/2/3
PACU 2/12/7/4 7/11/6/1 0.23
0/1/2/3
4 h postop 7/11/6/1 8/13/3/1 0.74
0/1/2/3
24 h postop 11/10/3/1 8/12/4/1 0.85
0/1/2/3
Rescue
analgesic (n)
2 (8%) 3 (12%) 0.64
Pain relief
0/1/2/3/4 0/2/6/12/5 0/4/5/12/4 0.83
PACU Z postanesthesia care unit.
Parecoxib for laryngeal microsurgery 577effective analgesia as did morphine within the first post-
operative day. Parecoxib was associated with lower overall
postoperative adverse in comparison with morphine. How-
ever, there was no significant difference in rescue analge-
sics, hemodynamic status, nausea, vomiting episodes,
pruritus, dizziness, or somnolence.
Postoperative sore throat is a common complaint that
affects patient satisfaction and activity; the incidence
varies from 14.4% to 45% after tracheal intubation [8e10].
It is also a common complication after laryngeal microsur-
gery. Postoperative sore throat after tracheal intubation
may result from pathological changes (such as epithelial
loss, glottis edema, and mucosal tears), trauma, and is
related to size and cuff of an endotracheal tube [11].
Furthermore, insertion of the laryngoscope during laryngeal
microsurgery may disrupt the pharyngeal mucosa over the
anterior tonsillar pillar with increased intrapharyngeal
pressure [12]. Because tracheal intubation may cause soreTable 3 Adverse events and satisfaction data in patients
receiving parecoxib or morphine.
Parecoxib
group (n Z 25)
Morphine
group (n Z 25)
p
Arrival PACU
Heart rate
(beat/min)
76.6  11.3 75.1  12.8 0.69
MAP (mmHg) 95.2  13.7 102.8  13.16 0.07
Adverse events
(overall)
0.047
PONV (n) 3 (12) 9 (36) 0.38
Pruritus (n) 2 (8) 4 (16) 0.31
Dizziness (n) 0 (0) 1 (4) 0.55
Somnolence (n) 1 (4) 2 (8) 0.15
Satisfaction 0 (0) 2 (8) 0.68
(1/2/3/4) 0/1/18/6 0/1/20/4
Data are presented as n (%) or mean  SD.
MAP Z mean arterial pressure, PACU Z postanesthesia care
unit; PONV Z postoperative nausea and vomiting.throat, two designs in the study were used to control this
contributing factor. First, an experienced anesthesiologist
was requested to perform all direct laryngoscopy. Second,
patients with anticipated difficult airway were not enrolled
and three patients with unexpected difficult laryngoscopy
were excluded.
COX enzymes are of physiological importance to pro-
duce prostaglandins. COX-1 is presented as a constitutive
enzyme to maintain cellular function in normal tissues,
whereas COX-2 is expressed as an inducible enzyme during
inflammation [13]. Both COX-2especific inhibitors and
traditional nonselective NSAIDs provide analgesia and anti-
inflammation by inhibiting COX-2 [14]. COX-2especific in-
hibitors have a better safety and tolerability because of
sparing COX-1 inhibition, which is associated with adverse
events such as gastrointestinal ulceration, renal impair-
ment, and bleeding [5]. Parecoxib sodium, the only
injectable COX-2especific inhibitor, is rapidly converted
to valdecoxib, which selectively inhibits COX-2 after
intravenous administration [15]. Parecoxib has been re-
ported as a valuable option for postoperative pain man-
agement because it is as effective as traditional NSAIDs,
has a better safety profile, and has a relatively longer
duration [16].
Both intravenous morphine and NSAIDs are commonly
used for postoperative pain control. The dose of morphine
titration may vary from 0.03 mg/kg to 0.15 mg/kg [17,18].
We chose 0.05 mg/kg as a titration dosage in daily practice.
With comparison of most intraoperative opioids (such as
fentanyl), the relatively slow onset and long duration of
morphine favor postoperative pain control. Intravenous
parecoxib also has a relative long duration (12 hours).
Because the procedure time of laryngeal microsurgery was
relatively short (within 35 minutes), the timing of study
drug injection was designed at anesthesia induction. Com-
mon dose of parecoxib was 40 mg for adults. However, we
took body weight into consideration (0.5 mg/kg) as for
morphine in this study, and our results revealed that this
dose was also effective.
According to the percentage of sore throat score
0 (pain free) within 24 hours, there was a pattern of longer
analgesic duration with parecoxib sodium compared to
morphine. Freedom from pain was found in 8%, 28%, and
44% at PACU, 4 hours, and 24 hours, respectively, post-
operatively for patients receiving parecoxib, whereas
pain-free status was found in 28%, 32%, and 32% at PACU, 4
hours, and 24 hours, respectively, postoperatively for pa-
tients receiving morphine. The analgesic activity of par-
ecoxib was comparable with morphine based on similar
sore throat score, number needed to give rescue analge-
sics, and pain relief score. Parecoxib sodium was well
tolerated in this trial. Opioid-related side effects may lead
to patient complaint, deteriorate upper airway obstruc-
tion, and even delay recovery [19]. In the current study,
overall adverse events were fewer in patients receiving
parecoxib. However, each opioid-related side effect
including nausea, vomiting, pruritus, dizziness, and som-
nolence was not significantly different between groups. It
was suggested that a reduction in opioid-related side ef-
fect would not be expected in single-dose treatment.
Nong et al. [20] demonstrated that parecoxib could reduce
morphine consumption but not morphine-related side
578 H.-F. Huang et al.effects. No adverse event related to parecoxib was
noticed in this study.
Conclusion
In this study, the results indicated that both parecoxib and
morphine are effective to attenuate postoperative sore
throat after laryngeal microsurgery. The overall adverse
events were less in single-dose parecoxib; this suggests that
parecoxib will be an effective and well-tolerated injectable
analgesic to manage postoperative sore throat after laryn-
geal microsurgery.
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